Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/11/2009CN100467064C Application of imatinib and midostaurin in preparation of medicines for treating gastrointestinal stromal tumors
03/11/2009CN100467061C Preparation method of scorpionfish-ink polysaccharide
03/11/2009CN100467060C Intratumorally administered lactoferrin in the treatment of malignant neoplasms diseases
03/11/2009CN100467059C Use of lactoferrin in the treatment of malignant neoplasms diseases
03/11/2009CN100467056C Ointment for unblocking collaterals and relieving pain and preparation process threreof
03/11/2009CN100467048C External used Chinese traditional medicine preparation for treating verruca vulgaris and preparing method thereof
03/11/2009CN100467040C Medicine composition for improving cognitive function of senile organism
03/11/2009CN100467033C Vegetal hepatoprotective agent and its manufacturing method
03/11/2009CN100467031C Medical use of burdock total lignanoid
03/11/2009CN100467028C Compound nucleotide oral liquor for improving immunity and its preparing method
03/11/2009CN100467027C Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine
03/11/2009CN100467026C Application of paeoniflorin in preparing blood enriching medicines
03/11/2009CN100467025C Use of asiaticoside or hydroxy asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels
03/11/2009CN100467024C Lornoxicam composition for injection and preparation process thereof
03/11/2009CN100467023C Use of N-(3-methoxy-5-methyl pyrazine-2-group)-2-(4-[1,3,4-oxadiazole-2-group]phenyl) pyridine-3-sulfanilamide as anticarcinogen
03/11/2009CN100467022C Application of 21(S) argatroban
03/11/2009CN100467021C Novel 2-oxo-heterocyclic compounds, and use the pharmaceutical compositions comprising the same
03/11/2009CN100467020C Matrix type patch containing bronchodilators
03/11/2009CN100467019C Anti-inflammatory cream and production thereof
03/11/2009CN100467016C Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
03/11/2009CN100467014C Method of preparing particles for agglomeration
03/11/2009CN100467012C Separately packed structural fatty milk, aminoacid and glucose injection composition and the preparation process
03/11/2009CA2639412A1 Prostaglandin e2 modulation and uses thereof
03/11/2009CA2638354A1 Association of an anti-atherothrombotic and an angiotensin converting enzyme inhibitor
03/11/2009CA2601558A1 Method of treating cancer by administration of 5-substituted nucleosides
03/10/2009US7501542 Highly-packed polycationic ammonium, sulfonium and phosphonium lipids
03/10/2009US7501541 N-(4-chloro-3-methoxy-phenyl)-N',N'-dimethyl-2-phenyl-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-malonamide; nervous system disorders like sleep disorders, insomnia, eating disorders, neurodegenerative disorders, sexual dysfuntion, pain, epi;epilepsy; improved pharmacokinetics
03/10/2009US7501539 2-(1-hydroxyalkyl)-cyclopent-2-en-1-one derivative starting material is thermally rearranged to a 2-alkylidene-3-oxo-cyclopentylacetate derivative; intermediates to perfumes such as methyl jasmonate
03/10/2009US7501525 Derivatives of benzimidazole and their use as medicaments
03/10/2009US7501524 Melacocortin receptors; analgesics; antiinflammatory agents; eating disorders; psychological disorders; anxiolytic agents; antidepressants; anticancer agents; aids; antiarthritic agents
03/10/2009US7501520 Regioselective halogenation of nicotine and substituted nicotines
03/10/2009US7501518 Via cyclocondensation of aryl/heteroaryl aldehyde with 1,3-acetonedicarboxylic acid
03/10/2009US7501516 3-Cyanoquinolines 4-substituted by a methylenedioxyphenyl group that is attached by a methylene, oxy, thio, sulfinyl, sulfonyl or amino group; antitumor agents
03/10/2009US7501515 Purified compound exhibits a melting endotherm with a peak temperature of about 262 degrees C. and an exotherm at about 253 degrees C.; solvent purification; useful in treating acne, female hirsutism and particularly benign prostatic hyperplasia
03/10/2009US7501513 Immunosuppressive effects of pteridine derivatives
03/10/2009US7501512 Chemical compounds
03/10/2009US7501511 Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome
03/10/2009US7501455 For parental injection of water insoluble drugs such as paclitaxel, propofol, amphotericin B, camptothecin, gemfibrozil and cyclosporin A; plasma protein such as serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin, in controlled aggregation state
03/10/2009US7501454 Cyclohexenone compounds from Antrodia camphorata to treat autoimmune diseases
03/10/2009US7501453 Cyclopropanes with central nervous system activity
03/10/2009US7501452 Treatment of xerostomia
03/10/2009US7501451 Mono-acylated o-phenylendiamines derivatives
03/10/2009US7501450 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
03/10/2009US7501449 2H -or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
03/10/2009US7501448 high yields, low cost process; easy solvent extraction; nontoxic, safe, environmentally friendly, low boiling point organic solvents; 1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl is reacted with 4'bromomethyl-biphenyl-2-carboxylic acid alkyl ester; industrial scale; hydrolysis
03/10/2009US7501447 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
03/10/2009US7501446 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors
03/10/2009US7501445 Imidazolidinone compounds
03/10/2009US7501444 3-Pyrid-3-yl- pyrazoles in which pyrazole ring is additionally substituted with a halogenated phenyl group; prenyl-protein transferase inhibitors
03/10/2009US7501443 Flavaxate derivatives as muscarinic receptor antagonists
03/10/2009US7501442 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-[2-((6-[2-(4-hydroxyphenyl)ethylamino]-hexanoyl)-methylamino)ethyl]piperidin-4-yl ester
03/10/2009US7501441 for treating uterine fibroid disease; [2-(4-hydroxyphenyl)-6-hydroxynaphthalen-1-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methane; therapy for post manupausal women
03/10/2009US7501440 blood sugar-reducing action; inhibit the activity of glycogen phosphorylase
03/10/2009US7501439 For treating Gaucher disease; improved Pharmacokinetics high purity, crystalline form; glucocerebrosidase inhibitors; beta glucosidase inhibitors
03/10/2009US7501438 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands
03/10/2009US7501437 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
03/10/2009US7501436 To treat irritable bowel syndrome; side effect reduction, improved pharmacodynamics and safety, more potent and selective; 2-imidazomethyl- pyrido(4,3-b)indol-1-one or -carbazol-1-one derivatives containing an ester group
03/10/2009US7501435 Inhibitors of checkpoint kinases
03/10/2009US7501434 Reduced gastrointestinal side effects of analgesic opioid therapy
03/10/2009US7501433 Opioid and opioid-like compounds and uses thereof
03/10/2009US7501432 Spiro-piperidine derivatives
03/10/2009US7501431 Physiologically active substances PF1270A, B and C substances
03/10/2009US7501430 e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders
03/10/2009US7501429 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
03/10/2009US7501428 Quinazoline thiazolinones
03/10/2009US7501427 Such as N6-(4,5-dihydrooxazol-2-yl)-N4-[3-methyl-4-(6-methylpyridin-3-yloxy)-phenyl]-quinazoline-4,6-diamine; for treatment of hyperproliferative disorders such as cancer
03/10/2009US7501426 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
03/10/2009US7501425 e.g. 1-Methyl-7-[4-(pyrazol-1-yl)phenylamino]pyrimido[4,5-d]pyrimidin-2(1H)-one; anticarcinogenic agents; restenosis, angiogenesis and atherosclerosis
03/10/2009US7501424 4-methyl-N-(5-methylthiazol-2-yl)-3-(4-thiazol-2-yl-pyrimidin-2-ylamino)-benzamide; amidation; protein kinase inhibitor; water soluble; stability; anticancer; Chronic Myelogenous Leukemia; lung, gastric, colon, pancreatic, hepatoma, prostatic, breast, encephalophyma, bladder, cervical, lymphoma
03/10/2009US7501423 Useful in the treatment of cancer; taxane-like effects on microtubule polymerization that are not substrates of P-glycoprotein; 6-chloro-5-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro- 1-methylethyl]pyrimidin-4-amine hemifumarate
03/10/2009US7501422 Prolinamide-tetrazole derivatives as NK3 receptor antagonists
03/10/2009US7501421 Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands
03/10/2009US7501420 1-benzoyl-3-(R)-methyl-4-[(7-(4-fluorophenyl)-6-azaindol-3-yl)-oxoacetyl]piperazine; antiviral agents, especially for the treatment of HIV and AIDS, either used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors
03/10/2009US7501419 4-Squarylpiperazine derivatives as antiviral agents
03/10/2009US7501418 e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity
03/10/2009US7501417 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
03/10/2009US7501416 Quinoxaline compounds and methods of using them
03/10/2009US7501415 Selective inhibitors of ERK protein kinase and uses thereof
03/10/2009US7501414 Substituted morpholine and thiomorpholine derivatives
03/10/2009US7501413 Dicarboxamide derivatives
03/10/2009US7501412 e.g. 4-(1-(2-hydroxyethyl)piperidin-4-yl)-2H-isoquinolin-1-one; poly(ADP-ribose)polymerase inhibitor; nicotinamide nucleotide (NAD) substrate; acute cerebral infarction
03/10/2009US7501411 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
03/10/2009US7501410 Methods of inhibiting BTK and SYK protein kinases
03/10/2009US7501409 A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction
03/10/2009US7501408 2-(R)-Cyclohexylmethyl-N-[1-(S)-methyl-2-(4-trifluoromethoxy-phenylamino)-ethyl]-4-oxo-4-thiomorpholin-4-yl-butyramide; selective in presence of at least one other cathepsin isozyme; antiinflammatory agent: arthritis, atherosclerosis
03/10/2009US7501407 Amide substituted pyrimidine compound; antiarthritic agents; antiischemic agents; antidiabetic agents; inflammatory bowel disease; antiproliferative agents; antiallergens
03/10/2009US7501406 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system
03/10/2009US7501405 Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
03/10/2009US7501404 Substituted azetidinones
03/10/2009US7501403 Bile acid or bile salt fatty acid conjugates
03/10/2009US7501402 Acidic oligosaccharide fragments produced by marine sponges and sea urchin embryos; potent stimulators of natural killer cells and gamma delta T cells; cancer, viral infections
03/10/2009US7501401 Administering oligonucleotide containing optimal nucleotide binding site for the transcription factor for therapy of disease associated with hyper-activated signal transduction pathways, particularly malignancy
03/10/2009US7501399 Immunoeffector compounds
03/10/2009US7501263 Nucleic acids encoding mammalian T-type calcium channels
03/10/2009US7501137 Process for controlling fecal hair excretion and trichobezoar formation
03/10/2009US7501135 Gastric acid secretion
03/10/2009US7501124 Administering allogenic or xenogeneric cell; complexing with antigen
03/10/2009US7501115 Providing a tissue removal system; removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells; processing at least a part of the adipose tissue to obtain a concentration
03/10/2009US7501114 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
03/10/2009US7501113 Aerosol formulations and aerosol delivery of buprenorphine